Roselina Lam, our Business Development and Licensing Manager, will attend the upcoming BIO Europe Spring on March 23rd-25th, 2020 in Paris, France. Contact her via the partnering platform or by e-mail, to learn more about our pipeline and discuss future partnerships. She is looking forward to meet you there!
4P-Pharma received the Seal of Excellence from the European Commission for its application related to the development of a disease modifier treatment for osteoarthritis, 4P-004 to the Horizon 2020 EIC Accelerator (SME instrument). Following evaluation by an international panel of independent experts, 4P-Pharma’s project was scored as a high-quality proposal in this highly competitive evaluation&hellip
A poster on 4P-004 entitled “Protective Effects Of Intra-Articular Formulated Liraglutide In Osteoarthritis” (#1970) will be presented during the 2nd Therapeutic Discoveries from Bench to First in Human Clinical Trials Conference, in Riyadh, Saudi Arabia, February 25th -27th, 2020.
4P-Pharma’s CEO, Revital Rattenbach, will attend the upcoming Biotech Showcase 2020 in San Francisco (USA), January 13th-15th, 2020. Contact us via the partnering platform or by e-mail to schedule a meeting and discuss future collaborations.
Roselina Lam, our Business Developer, will be attending the upcoming Biofit 2019 conference in Marseille on December 10th-11th. To learn more about our pipeline and partnerships, contact us via the partnering platform or by e-mail. Looking forward to meet you there!